Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Fujimoto, J., Kurasawa, O., Takagi, T., Liu, X., Banno, H., Kojima, T., Asano, Y., Nakamura, A., Nambu, T., Hata, A., Ishii, T., Sameshima, T., Debori, Y., Miyamoto, M., Klein, M.G., Tjhen, R., Sang, B.C., Levin, I., Lane, S.W., Snell, G.P., Li, K., Kefala, G., Hoffman, I.D., Ding, S.C., Cary, D.R., Mizojiri, R.(2019) ACS Med Chem Lett 10: 1498-1503
- PubMed: 31620240 
- DOI: 10.1021/acsmedchemlett.9b00400
- Primary Citation of Related Structures:  
6N3L, 6N3N, 6N3O - PubMed Abstract: 
General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibi ...